Author: admin

“Musculoskeletal Pain Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Musculoskeletal Pain Market.

The Musculoskeletal Pain Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Musculoskeletal Pain Pipeline Report:

• Companies across the globe are diligently working toward developing novel Musculoskeletal Pain treatment therapies with a considerable amount of success over the years.

• Musculoskeletal Pain companies working in the treatment market are Mesoblast, Regenron, Teva, Taiwan Liposome, Eli Lilly, Axsome Therapeutics, Biosplice Therapeutics, Centrexion Therapeutics, Techfields Pharma, and others, are developing therapies for the Musculoskeletal Pain treatment

• Emerging Musculoskeletal Pain therapies in the different phases of clinical trials are- MPC-06-ID, Fasinumab, TLC599, Eli Lilly, AXS-14, Lorecivivint, CNTX-4975, X0002, and others are expected to have a significant impact on the Musculoskeletal Pain market in the coming years.

Musculoskeletal Pain Overview

Musculoskeletal pain refers to pain that affects the muscles, bones, tendons, ligaments, and nerves. It is a common condition that can be caused by various factors, including injury, overuse, inflammation, or underlying medical conditions. Musculoskeletal pain can be acute (short-term) or chronic (long-term), and it often results in discomfort, stiffness, and reduced mobility. Common causes include conditions like arthritis, back pain, sprains, strains, and fibromyalgia. The pain can range from mild to severe and may be localized or widespread. Treatment typically involves pain management strategies such as medications, physical therapy, exercise, and sometimes surgical interventions.

Get a Free Sample PDF Report to know more about Musculoskeletal Pain Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/musculoskeletal-pain-pipeline-insight

Emerging Musculoskeletal Pain Drugs Under Different Phases of Clinical Development Include:

• MPC-06-ID: Mesoblast

• Fasinumab: Regenron/Teva

• TLC599: Taiwan Liposome

• LY3016859: Eli Lilly

• AXS-14: Axsome Therapeutics

• Lorecivivint: Biosplice Therapeutics

• CNTX-4975: Centrexion Therapeutics

• X0002: Techfields Pharma

Musculoskeletal Pain Pipeline Therapeutics Assessment

• Musculoskeletal Pain Assessment by Product Type

• Musculoskeletal Pain By Stage and Product Type

• Musculoskeletal Pain Assessment by Route of Administration

• Musculoskeletal Pain By Stage and Route of Administration

• Musculoskeletal Pain Assessment by Molecule Type

• Musculoskeletal Pain by Stage and Molecule Type

DelveInsight’s Musculoskeletal Pain Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Musculoskeletal Pain product details are provided in the report. Download the Musculoskeletal Pain pipeline report to learn more about the emerging Musculoskeletal Pain therapies

Some of the key companies in the Musculoskeletal Pain Therapeutics Market include:

Key companies developing therapies for Musculoskeletal Pain are – Eli Lilly and Company, Amgen Inc., Pfizer Inc., Johnson & Johnson, Novartis AG, and others.

Musculoskeletal Pain Pipeline Analysis:

The Musculoskeletal Pain pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Musculoskeletal Pain with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Musculoskeletal Pain Treatment.

• Musculoskeletal Pain key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Musculoskeletal Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Musculoskeletal Pain market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Musculoskeletal Pain drugs and therapies

Musculoskeletal Pain Pipeline Market Drivers

• Increasing prevalence, Advancements in treatment options, Growing awareness, Aging population, Rising healthcare expenditures, are some of the important factors that are fueling the Musculoskeletal Pain Market.

Musculoskeletal Pain Pipeline Market Barriers

• However, High cost of development, Stringent regulatory approval processes, Limited understanding of complex pain mechanisms, and other factors are creating obstacles in the Musculoskeletal Pain Market growth.

Scope of Musculoskeletal Pain Pipeline Drug Insight

• Coverage: Global

• Key Musculoskeletal Pain Companies: Mesoblast, Regenron, Teva, Taiwan Liposome, Eli Lilly, Axsome Therapeutics, Biosplice Therapeutics, Centrexion Therapeutics, Techfields Pharma, and others

• Key Musculoskeletal Pain Therapies: MPC-06-ID, Fasinumab, TLC599, Eli Lilly, AXS-14, Lorecivivint, CNTX-4975, X0002, and others

• Musculoskeletal Pain Therapeutic Assessment: Musculoskeletal Pain current marketed and Musculoskeletal Pain emerging therapies

• Musculoskeletal Pain Market Dynamics: Musculoskeletal Pain market drivers and Musculoskeletal Pain market barriers

Request for Sample PDF Report for Musculoskeletal Pain Pipeline Assessment and clinical trials

Table of Contents

1. Musculoskeletal Pain Report Introduction

2. Musculoskeletal Pain Executive Summary

3. Musculoskeletal Pain Overview

4. Musculoskeletal Pain- Analytical Perspective In-depth Commercial Assessment

5. Musculoskeletal Pain Pipeline Therapeutics

6. Musculoskeletal Pain Late Stage Products (Phase II/III)

7. Musculoskeletal Pain Mid Stage Products (Phase II)

8. Musculoskeletal Pain Early Stage Products (Phase I)

9. Musculoskeletal Pain Preclinical Stage Products

10. Musculoskeletal Pain Therapeutics Assessment

11. Musculoskeletal Pain Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Musculoskeletal Pain Key Companies

14. Musculoskeletal Pain Key Products

15. Musculoskeletal Pain Unmet Needs

16 . Musculoskeletal Pain Market Drivers and Barriers

17. Musculoskeletal Pain Future Perspectives and Conclusion

18. Musculoskeletal Pain Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Musculoskeletal Pain Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Mesoblast, Regenron, Teva, Taiwan Liposome, Eli Lilly, Axsome Therapeutics

DelveInsight’s “Thrombotic Thrombocytopenic Purpura Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Thrombotic Thrombocytopenic Purpura, historical and forecasted epidemiology as well as the Thrombotic Thrombocytopenic Purpura market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Thrombotic Thrombocytopenic Purpura market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thrombotic Thrombocytopenic Purpura Market Forecast

Some of the key facts of the Thrombotic Thrombocytopenic Purpura Market Report:

• The Thrombotic Thrombocytopenic Purpura market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In August 2024, The European Commission (EC) has granted Takeda approval to market ADZYNMA (recombinant ADAMTS13), making it the first and only enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP) in the European Union (EU).

• According to Borborema et al. (2020), every 26 years, a family with cTTP has been found by the Oklahoma TTP-HUS registry, which represents a population base of 2 million people. According to the experts, there are 1.5 patients with cTTP for every million people

• According to a study by Dorland et al. (2019), cases of cTTP were found in the age ranges of 0–10 years, 10–20 years, 20–30 years, 40–50 years, >50–60 years, 60–70 years, and 70–80 years in 15.8%, 16.6%, 23.3%, 19.1%, 14.1%, 5%, 4.16%, and 1.6%, respectively

• According to Borborema et al. (2020), every 26 years, a family with cTTP has been found by the Oklahoma TTP-HUS registry, which represents a population base of 2 million people. According to the experts, there are 1.5 patients with cTTP for every million people

• Key Thrombotic Thrombocytopenic Purpura Companies: Global Blood Therapeutics, Sanofi, Carelon Research, Archemix Corp., Eisai Inc., Biopharma Plasma, Beijing InnoCare Pharma, Shionogi, Takeda, and others

• Key Thrombotic Thrombocytopenic Purpura Therapies: Inclacumab, Caplacizumab, Rituximab, ARC 1779, Eltrombopag, Intravenous immunoglobulin (IVIG), Orelabrutinib, Lusutrombopag, TAK-079, and others

• The Thrombotic Thrombocytopenic Purpura epidemiology based on gender analyzed that it was seen that women represented 61.3% of Medicare FFS beneficiaries, 67.5% of Medicare advantage plan members, 66.3% of commercial plan members, and 79.1% of managed Medicaid members

• The Thrombotic Thrombocytopenic Purpura market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Thrombotic Thrombocytopenic Purpura pipeline products will significantly revolutionize the Thrombotic Thrombocytopenic Purpura market dynamics.

Thrombotic Thrombocytopenic Purpura Overview

Thrombotic Thrombocytopenic Purpura (TTP) is a rare and potentially life-threatening blood disorder characterized by the formation of small blood clots (thrombi) throughout the body. These clots can block blood flow to vital organs, leading to organ damage. TTP is associated with a low platelet count (thrombocytopenia), which results in easy bruising, purplish spots on the skin (purpura), and increased bleeding risk. It can also cause symptoms such as fatigue, confusion, kidney dysfunction, and fever. The condition is often triggered by an autoimmune response that inhibits the activity of an enzyme called ADAMTS13, leading to the formation of clots. Treatment typically involves plasma exchange therapy, corticosteroids, and immunosuppressive drugs.

Get a Free sample for the Thrombotic Thrombocytopenic Purpura Market Report:

https://www.delveinsight.com/report-store/thrombotic-thrombocytopenic-purpura-market

Thrombotic Thrombocytopenic Purpura Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Thrombotic Thrombocytopenic Purpura Epidemiology Segmentation:

The Thrombotic Thrombocytopenic Purpura market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Thrombotic Thrombocytopenic Purpura

• Prevalent Cases of Thrombotic Thrombocytopenic Purpura by severity

• Gender-specific Prevalence of Thrombotic Thrombocytopenic Purpura

• Diagnosed Cases of Episodic and Chronic Thrombotic Thrombocytopenic Purpura

Download the report to understand which factors are driving Thrombotic Thrombocytopenic Purpura epidemiology trends @ Thrombotic Thrombocytopenic Purpura Epidemiology Forecast

Thrombotic Thrombocytopenic Purpura Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Thrombotic Thrombocytopenic Purpura market or expected to get launched during the study period. The analysis covers Thrombotic Thrombocytopenic Purpura market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Thrombotic Thrombocytopenic Purpura Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Thrombotic Thrombocytopenic Purpura Therapies and Key Companies

• Inclacumab: Global Blood Therapeutics

• Caplacizumab: Sanofi

• Rituximab: Carelon Research

• ARC 1779: Archemix Corp.

• Eltrombopag: Eisai Inc.

• Intravenous immunoglobulin (IVIG): Biopharma Plasma

• Orelabrutinib: Beijing InnoCare Pharma

• Lusutrombopag: Shionogi

• TAK-079: Takeda

Discover more about therapies set to grab major Thrombotic Thrombocytopenic Purpura market share @ Thrombotic Thrombocytopenic Purpura Treatment Market

Thrombotic Thrombocytopenic Purpura Market Drivers

• The use of off-label branded and generic prescription medications targeted at individual symptoms of Netherton Syndrome, including antiepileptics, antipsychotics, antidepressants and benzodiazepines.

• Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of Netherton Syndrome.

Thrombotic Thrombocytopenic Purpura Market Barriers

• New therapeutic options are needed to address the unmet need for effective and curative therapies for Netherton Syndrome. This has created an opportunity for key players to develop novel therapies targeted towards this indication

Scope of the Thrombotic Thrombocytopenic Purpura Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Thrombotic Thrombocytopenic Purpura Companies: Global Blood Therapeutics, Sanofi, Carelon Research, Archemix Corp., Eisai Inc., Biopharma Plasma, Beijing InnoCare Pharma, Shionogi, Takeda, and others

• Key Thrombotic Thrombocytopenic Purpura Therapies: Inclacumab, Caplacizumab, Rituximab, ARC 1779, Eltrombopag, Intravenous immunoglobulin (IVIG), Orelabrutinib, Lusutrombopag, TAK-079, and others

• Thrombotic Thrombocytopenic Purpura Therapeutic Assessment: Thrombotic Thrombocytopenic Purpura current marketed and Thrombotic Thrombocytopenic Purpura emerging therapies

• Thrombotic Thrombocytopenic Purpura Market Dynamics: Thrombotic Thrombocytopenic Purpura market drivers and Thrombotic Thrombocytopenic Purpura market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Thrombotic Thrombocytopenic Purpura Unmet Needs, KOL’s views, Analyst’s views, Thrombotic Thrombocytopenic Purpura Market Access and Reimbursement

To know more about Thrombotic Thrombocytopenic Purpura companies working in the treatment market, visit @ Thrombotic Thrombocytopenic Purpura Clinical Trials and Therapeutic Assessment

Table of Contents

1. Thrombotic Thrombocytopenic Purpura Market Report Introduction

2. Executive Summary for Thrombotic Thrombocytopenic Purpura

3. SWOT analysis of Thrombotic Thrombocytopenic Purpura

4. Thrombotic Thrombocytopenic Purpura Patient Share (%) Overview at a Glance

5. Thrombotic Thrombocytopenic Purpura Market Overview at a Glance

6. Thrombotic Thrombocytopenic Purpura Disease Background and Overview

7. Thrombotic Thrombocytopenic Purpura Epidemiology and Patient Population

8. Country-Specific Patient Population of Thrombotic Thrombocytopenic Purpura

9. Thrombotic Thrombocytopenic Purpura Current Treatment and Medical Practices

10. Thrombotic Thrombocytopenic Purpura Unmet Needs

11. Thrombotic Thrombocytopenic Purpura Emerging Therapies

12. Thrombotic Thrombocytopenic Purpura Market Outlook

13. Country-Wise Thrombotic Thrombocytopenic Purpura Market Analysis (2020–2034)

14. Thrombotic Thrombocytopenic Purpura Market Access and Reimbursement of Therapies

15. Thrombotic Thrombocytopenic Purpura Market Drivers

16. Thrombotic Thrombocytopenic Purpura Market Barriers

17. Thrombotic Thrombocytopenic Purpura Appendix

18. Thrombotic Thrombocytopenic Purpura Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thrombotic Thrombocytopenic Purpura Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Global Blood Therapeutics, Sanofi, Carelon Research, Archemix Corp., Eisai Inc

DelveInsight’s “Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chronic Obstructive Pulmonary Disease, historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Obstructive Pulmonary Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Obstructive Pulmonary Disease Market Forecast

Some of the key facts of the Chronic Obstructive Pulmonary Disease Market Report:

• The Chronic Obstructive Pulmonary Disease market size was valued ~USD 16,075 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In January 2025, Aer Therapeutics (“Aer”), a biopharmaceutical company focused on developing innovative inhaled treatments for mucus-related lung diseases, has announced the dosing of the first patient in its Phase 2a proof-of-concept (“POC”) clinical trial of fexlamose (previously known as “AER-01”) for Chronic Obstructive Pulmonary Disease (“COPD”). The Phase 2a POC study (“AER-01-002”) is a randomized, double-blind, placebo-controlled trial that will administer fexlamose once daily for 28 days to COPD patients. Aer is applying a novel approach to identify and treat patients with mucus plug-associated COPD.

• In 2023, EU4 and the UK recorded an estimated market value of USD 3,361 million, with expectations for significant growth at a strong CAGR. Among the European nations, Germany held the largest market share, followed by Italy, France, and Spain. The UK had the smallest market share in that year.

• DelveInsight analysts estimate that there were around 44.2 million diagnosed prevalent cases of COPD in the 7MM in 2023.

• The United States had the highest diagnosed prevalent population of COPD among the 7MM countries. According to DelveInsight’s estimates, the total diagnosed prevalent cases of COPD in the US were approximately 18.3 million in 2023, with a projected increase over the forecast period due to factors such as higher smoking rates, better diagnosis, and growing awareness among patients.

• DelveInsight’s estimates suggest that the total diagnosed prevalent cases of COPD in the EU4 and the UK were approximately 18.6 million in 2023. A significant rise in cases is expected across all contributing countries throughout the study period. Among the EU4 nations, Germany reported the highest proportion of COPD cases, while Spain had the fewest cases.

• In 2023, the UK saw approximately 1.7 million diagnosed cases of COPD in females and around 2 million in males, with both figures expected to rise during the forecast period (2024–2034). The higher prevalence in females is likely attributed to a mix of factors, such as genetics, environmental influences, and healthcare disparities, among others.

• Key Chronic Obstructive Pulmonary Disease Companies: Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others

• Key Chronic Obstructive Pulmonary Disease Therapies: Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others.

• The Chronic Obstructive Pulmonary Disease epidemiology based on gender analyzed that the majority of cases of COPD are of female as compared to male, in the US

• The Chronic Obstructive Pulmonary Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Obstructive Pulmonary Disease pipeline products will significantly revolutionize the Chronic Obstructive Pulmonary Disease market dynamics.

Chronic Obstructive Pulmonary Disease Overview

Chronic obstructive pulmonary disease (COPD) is a widespread, treatable, and avoidable illness marked by ongoing respiratory symptoms and restricted airflow because of abnormalities in the airways or alveoli, which are typically brought on by prolonged exposure to harmful particles or gases.

Get a Free sample for the Chronic Obstructive Pulmonary Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market

Chronic Obstructive Pulmonary Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Obstructive Pulmonary Disease Epidemiology Segmentation:

The Chronic Obstructive Pulmonary Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Chronic Obstructive Pulmonary Disease

• Prevalent Cases of Chronic Obstructive Pulmonary Disease by severity

• Gender-specific Prevalence of Chronic Obstructive Pulmonary Disease

• Diagnosed Cases of Episodic and Chronic Chronic Obstructive Pulmonary Disease

Download the report to understand which factors are driving Chronic Obstructive Pulmonary Disease epidemiology trends @ Chronic Obstructive Pulmonary Disease Epidemiology Forecast

Chronic Obstructive Pulmonary Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Obstructive Pulmonary Disease market or expected to get launched during the study period. The analysis covers Chronic Obstructive Pulmonary Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Obstructive Pulmonary Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Obstructive Pulmonary Disease Therapies and Key Companies

• Itepekimab/SAR440340/REGN3500: Regeneron Pharmaceuticals/Sanofi

• Dupilumab/SAR231893 (Dupixent): Regeneron Pharmaceuticals/Sanofi

• Tozorakimab (MEDI3506): AstraZeneca/MedImmune LLC

• FASENRA (Benralizumab): AstraZeneca

• Tezspire (Tezepelumab): AstraZeneca

• Astegolimab (MSTT1041A, AMG 282, RG6149): Genentech, Inc.

• SB240563 (Mepolizumab)/NUCALA: GlaxoSmithKline

• Ensifentrine (RPL554): Verona Pharma plc

• EP395: EpiEndo Pharmaceuticals

• SelK2: Tetherex Pharmaceuticals

• Mitiperstat (AZD4831): AstraZeneca

• CHF6001/Tanimilast: Chiesi Farmaceutici S.p.A.

• SNG001 (IFN-β): Synairgen Research Ltd.

• Acumapimod (BCT-197): Mereo Biopharma

• Zofin: Organicell Regenerative Medicine

• PUL-042: Pulmotect, Inc.

• MV130: Inmunotek S.L.

• GSK3923868: GlaxoSmithKline

• PUR1800: PULMATRiX

• GRC 39815: GLENMARK PHARMACEUTICALS LTD

• DMX-700: Dimerix Limited

Discover more about therapies set to grab major Chronic Obstructive Pulmonary Disease market share @ Chronic Obstructive Pulmonary Disease Treatment Landscape

Chronic Obstructive Pulmonary Disease Market Strengths

• The prevalence of COPD is increasing dramatically in recent years due to the higher smoking prevalence and aging populations in many countries.

Chronic Obstructive Pulmonary Disease Market Opportunities

• There is a growing demand for fixed-dose combinations as combination therapy can enhance and prolong the effects of monocomponent.

Scope of the Chronic Obstructive Pulmonary Disease Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Chronic Obstructive Pulmonary Disease Companies: Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others

• Key Chronic Obstructive Pulmonary Disease Therapies: Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others

• Chronic Obstructive Pulmonary Disease Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and Chronic Obstructive Pulmonary Disease emerging therapies

• Chronic Obstructive Pulmonary Disease Market Dynamics: Chronic Obstructive Pulmonary Disease market drivers and Chronic Obstructive Pulmonary Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Chronic Obstructive Pulmonary Disease Unmet Needs, KOL’s views, Analyst’s views, Chronic Obstructive Pulmonary Disease Market Access and Reimbursement

To know more about Chronic Obstructive Pulmonary Disease companies working in the treatment market, visit @ Chronic Obstructive Pulmonary Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Chronic Obstructive Pulmonary Disease Market Report Introduction

2. Executive Summary for Chronic Obstructive Pulmonary Disease

3. SWOT analysis of Chronic Obstructive Pulmonary Disease

4. Chronic Obstructive Pulmonary Disease Patient Share (%) Overview at a Glance

5. Chronic Obstructive Pulmonary Disease Market Overview at a Glance

6. Chronic Obstructive Pulmonary Disease Disease Background and Overview

7. Chronic Obstructive Pulmonary Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Obstructive Pulmonary Disease

9. Chronic Obstructive Pulmonary Disease Current Treatment and Medical Practices

10. Chronic Obstructive Pulmonary Disease Unmet Needs

11. Chronic Obstructive Pulmonary Disease Emerging Therapies

12. Chronic Obstructive Pulmonary Disease Market Outlook

13. Country-Wise Chronic Obstructive Pulmonary Disease Market Analysis (2020–2034)

14. Chronic Obstructive Pulmonary Disease Market Access and Reimbursement of Therapies

15. Chronic Obstructive Pulmonary Disease Market Drivers

16. Chronic Obstructive Pulmonary Disease Market Barriers

17. Chronic Obstructive Pulmonary Disease Appendix

18. Chronic Obstructive Pulmonary Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Obstructive Pulmonary Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma

The Cough in Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Cough in Idiopathic Pulmonary Fibrosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cough in Idiopathic Pulmonary Fibrosis Market.

Some of the key takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Cough in Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.

• Cough in Idiopathic Pulmonary Fibrosis companies working in the treatment market are NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others, are developing therapies for the Cough in Idiopathic Pulmonary Fibrosis treatment

• Emerging Cough in Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are – Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others are expected to have a significant impact on the Cough in Idiopathic Pulmonary Fibrosis market in the coming years.

• In December 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on developing the investigational treatment Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced a positive result from the planned sample size re-estimation (SSRE) for its ongoing Phase 2b CORAL trial in IPF patients with chronic cough. The outcome indicates that no adjustments are needed to the current sample size for the trial (N=160).

• In August 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced that the majority of the 60 planned sites for the Phase 2b CORAL trial have been initiated. The trial, which aims to enroll around 160 patients, will include a sample size re-estimation (SSRE) in the fourth quarter of this year, once 50% of patients are evaluable for the primary endpoint. Barring any adjustments, topline results are expected in the first half of 2025.

• In May 2024, Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced topline results from a 12-week, randomized, double-blind, placebo-controlled trial of bexotegrast (PLN-74809) conducted at Massachusetts General Hospital. The trial evaluated changes in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis (IPF), a condition marked by excessive collagen buildup in the lungs.

• In March 2024, US-based Seyltx finalized an agreement to acquire Algernon Pharmaceuticals’ chronic cough therapy, ifenprodil (NP-120). Algernon received $2 million and a 20% equity stake in Seyltx as part of the deal. Ifenprodil, an N-methyl-D-aspartate (NMDA) receptor antagonist, specifically targets the NMDA type subunit 2B (GluN2B). Data from the Phase II trial conducted in Australia and New Zealand demonstrated a reduction in cough count among patients with idiopathic pulmonary fibrosis (IPF) and chronic cough compared to baseline.

Cough in Idiopathic Pulmonary Fibrosis Overview

Cough in Idiopathic Pulmonary Fibrosis (IPF) is a common and distressing symptom of this chronic lung disease. IPF causes scarring and thickening of the lung tissue, leading to breathing difficulties and persistent dry, non-productive cough. The exact cause of cough in IPF is not fully understood, but it is believed to result from the irritation caused by the fibrosis (scarring) of the lung tissue, which can trigger the cough reflex. This cough is often persistent, worsening over time, and can significantly impact a patient’s quality of life. Treatment typically focuses on managing symptoms and slowing the progression of IPF.

Get a Free Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight

Emerging Cough in Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:

• Orvepitant Maleate: NeRRe Therapeutics

• Haduvio (nalbuphine ER): Trevi Therapeutics

• ME-015 (Suplatast Tosilate): Melius Pharma AB

• BI 1839100: Boehringer Ingelheim

Cough in Idiopathic Pulmonary Fibrosis Route of Administration

Cough in Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Cough in Idiopathic Pulmonary Fibrosis Molecule Type

Cough in Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

• Cough in Idiopathic Pulmonary Fibrosis Assessment by Product Type

• Cough in Idiopathic Pulmonary Fibrosis By Stage and Product Type

• Cough in Idiopathic Pulmonary Fibrosis Assessment by Route of Administration

• Cough in Idiopathic Pulmonary Fibrosis By Stage and Route of Administration

• Cough in Idiopathic Pulmonary Fibrosis Assessment by Molecule Type

• Cough in Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight’s Cough in Idiopathic Pulmonary Fibrosis Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Cough in Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Cough in Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Cough in Idiopathic Pulmonary Fibrosis therapies

Some of the key companies in the Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market include:

Key companies developing therapies for Cough in Idiopathic Pulmonary Fibrosis are – Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, NeRRe Therapeutics, Trevi Therapeutics, Cellular Sciences, Emphycorp, and others

Cough in Idiopathic Pulmonary Fibrosis Pipeline Analysis:

The Cough in Idiopathic Pulmonary Fibrosis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Cough in Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cough in Idiopathic Pulmonary Fibrosis Treatment.

• Cough in Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Cough in Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cough in Idiopathic Pulmonary Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis drugs and therapies

Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Drivers

• High Unmet Need, Growing Patient Population, Advancements in Research, Regulatory Support, Increased Investment, are some of the important factors that are fueling the Cough in Idiopathic Pulmonary Fibrosis Market.

Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Barriers

• However, Complex Disease Pathophysiology, Clinical Trial Challenges, Competitive Landscape, and other factors are creating obstacles in the Cough in Idiopathic Pulmonary Fibrosis Market growth.

Scope of Cough in Idiopathic Pulmonary Fibrosis Pipeline Drug Insight

• Coverage: Global

• Key Cough in Idiopathic Pulmonary Fibrosis Companies: NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others

• Key Cough in Idiopathic Pulmonary Fibrosis Therapies: Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others

• Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Cough in Idiopathic Pulmonary Fibrosis current marketed and Cough in Idiopathic Pulmonary Fibrosis emerging therapies

• Cough in Idiopathic Pulmonary Fibrosis Market Dynamics: Cough in Idiopathic Pulmonary Fibrosis market drivers and Cough in Idiopathic Pulmonary Fibrosis market barriers

Request for Sample PDF Report for Cough in Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials

Table of Contents

1. Cough in Idiopathic Pulmonary Fibrosis Report Introduction

2. Cough in Idiopathic Pulmonary Fibrosis Executive Summary

3. Cough in Idiopathic Pulmonary Fibrosis Overview

4. Cough in Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics

6. Cough in Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)

7. Cough in Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)

8. Cough in Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)

9. Cough in Idiopathic Pulmonary Fibrosis Preclinical Stage Products

10. Cough in Idiopathic Pulmonary Fibrosis Therapeutics Assessment

11. Cough in Idiopathic Pulmonary Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cough in Idiopathic Pulmonary Fibrosis Key Companies

14. Cough in Idiopathic Pulmonary Fibrosis Key Products

15. Cough in Idiopathic Pulmonary Fibrosis Unmet Needs

16 . Cough in Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

17. Cough in Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion

18. Cough in Idiopathic Pulmonary Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cough in Idiopathic Pulmonary Fibrosis Pipeline 2024: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi